COMPANY NEWS
Essex Bio-Technology Included by MSCI as A Constituent of The MSCI China Small Cap Index
2019.05.15
Download
Hong Kong, 15 May 2019
Essex Bio-Technology Limited (“EssexBio” or the“Group” or the Company, Stock code: 1061) is pleased to announce that the Company has been included by Morgan Stanley Capital International (“MSCI”) as a constituent of the MSCI China Small Cap Index, which will be effective as of the close of 28 May 2019.
MSCI is a leading provider of global equity indexes and benchmark related products and services to investors worldwide. The MSCI China Small Cap Index is designed to measure the performance of the small cap segment of the China market. Constituent stocks included in the index are generally companies with operating base in China, demonstrating excellent performance and development prospect.
The Board of Directors believe that the inclusion of the Company into above global index proved the worldwide recognition of the Company’s track record in capital market. As MSCI is one of the most widely-used international equity benchmark by global institutional investors, more engagement by international funds is expected and should further contribute to the liquidity and market value of the Company, enhancing its corporate image and accelerating the future development of its business in the biopharmaceutical industry.
Essex Bio-Technology Limited (“EssexBio” or the“Group” or the Company, Stock code: 1061) is pleased to announce that the Company has been included by Morgan Stanley Capital International (“MSCI”) as a constituent of the MSCI China Small Cap Index, which will be effective as of the close of 28 May 2019.
MSCI is a leading provider of global equity indexes and benchmark related products and services to investors worldwide. The MSCI China Small Cap Index is designed to measure the performance of the small cap segment of the China market. Constituent stocks included in the index are generally companies with operating base in China, demonstrating excellent performance and development prospect.
The Board of Directors believe that the inclusion of the Company into above global index proved the worldwide recognition of the Company’s track record in capital market. As MSCI is one of the most widely-used international equity benchmark by global institutional investors, more engagement by international funds is expected and should further contribute to the liquidity and market value of the Company, enhancing its corporate image and accelerating the future development of its business in the biopharmaceutical industry.
Related news
Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%
2024-03-18
Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%
2023-08-16
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
2023-07-26
Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready
2023-03-08
Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)
2021-10-27
Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia
2021-04-20
Essex-Biotechnology Announces Bevacizumab for wAMD Has Received Clinical Trial Approval in Australia
2021-01-29
Essex Bio-Technology and Antikor Biopharma Forge Strategic Alliance in FDC for Cancer Treatment
2019-08-02
粵公網安備 44049102496184號